Ratings Opthea Limited

Equities

OPT

AU000000OPT2

Market Closed - Australian S.E. Other stock markets 02:10:46 2024-05-10 EDT			5-day change	1st Jan Change
0.68 ^AUD	+7.09%		+11.48%	+19.30%

04-03	Opthea Limited Announces Board Changes	CI
02-29	Opthea Posts H1 FY24 Loss per Share of $0.1623; R&D Expenses Jump	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' opinions have been revised negatively.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
OPTHEA LIMITED	+19.30%	278M	C-
MODERNA, INC.	+18.48%	47.02B	B-
LONZA GROUP AG	+48.77%	41.86B	A
IQVIA HOLDINGS INC.	+0.51%	41.76B	B
CELLTRION, INC.	-4.27%	28.8B	C
ICON PUBLIC LIMITED COMPANY	+11.85%	26.05B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.17%	19.15B	B
BIO-TECHNE CORPORATION	+4.65%	12.55B	B+
MEDPACE HOLDINGS, INC.	+29.83%	12.34B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.91%	11.82B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes